Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. Issue 1 (January 2023)

• Record Type: Journal Article
• Authors: Boyer, Claire; Sefrioui, David; Cohen, Romain; Chautard, Romain; Perrier, Marine; Lebrun, Hugo; Goujon, Gael; Hautefeuille, Vincent; Dior, Marie; Walter, Thomas; Mary, Florence; Manfredi, Silvain; Caroli-Bosc, Francois-Xavier; Cervantes, Baptiste; Coriat, Romain; Deluche, Elise; Zaanan, Aziz; Olivier, Raphael; Bouché, Olivier; Piessen, Guillaume; Lecomte, Thierry; Louvet, Christophe; Michel, Pierre; Aparicio, Thomas; André, Thierry; Taieb, Julien; Randrian, Violaine; Tougeron, David
• Is Part Of: Digestive and liver disease. Volume 55:Issue 1(2023)
• Page Start: 123
• Page End: 130
• Publication Date: 2023-01
• Subjects: Deficient mismatch repair -- Gastric adenocarcinomas -- Microsatellite instability -- Small bowel adenocarcinomas; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2022.03.011
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Data on outcomes of microsatellite instable and/or mismatch repair deficient (dMMR/MSI) digestive non-colorectal tumors are limited. Aims: To evaluate overall survival (OS) of patients with dMMR/MSI digestive non-colorectal tumor. Methods: All consecutive patients with a dMMR/MSI digestive non-colorectal tumor were included in this French retrospective multicenter study. Results: One hundred and sixteen patients were included with a mean age of 63.6 years and 32.6% with a Lynch syndrome. Most tumors were oesophago-gastric (54.3%) or small bowel (32.8%) adenocarcinomas and at a localized stage at diagnosis (86.7%). In patients with localized tumors and R0 resection, median OS was 134.0 ± 64.2 months. Median disease-free survival (DFS) was 100.3 ± 65.7 months. Considering oesophago-gastric tumors, median DFS was improved when chemotherapy was added to surgery (not reached versus 22.8 ± 10.0 months, p = 0.03). In patients with advanced tumors treated by chemotherapy, median OS was 14.2 ± 1.9 months and median progression-free survival was 7.4 ± 1.6 months. Conclusion: dMMR/MSI digestive non-colorectal tumors are mostly diagnosed at a non-metastatic stage with a good prognosis. Advanced dMMR/MSI digestive non-colorectal tumors have a poor prognosis with standard chemotherapy.